Daljit Singh Aurora Sells 21,055 Shares of Neumora Therapeutics (NASDAQ:NMRA) Stock

Key Points

• Insider selling: Daljit Singh Aurora sold 21,055 Neumora Therapeutics shares for approximately $33,688, reducing his position by 30.16% to 48,750 shares. He also reported multiple sales from August 17–21.
• Stock performance and finances: NMRA rose to $1.63, with a $306.3 million market capitalization, but remains well below its 200-day moving average of $2.10. The company posted a quarterly loss of $0.23 per share, slightly better than estimates.
• Analyst outlook: Analysts maintain a “Moderate Buy” consensus and an average price target of $6.57, though several firms recently cut their targets. Price targets now range from $4 to $5 among the highlighted firms, while one rating agency has a “sell” assessment.

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) insider Daljit Singh Aurora sold 21,055 shares of the business's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $1.60, for a total value of $33,688.00. Following the sale, the insider owned 48,750 shares of the company's stock, valued at approximately $78,000. This represents a 30.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Daljit Singh Aurora also recently made the following trade(s):

• On Thursday, August 20th, Daljit Singh Aurora sold 66,711 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.51, for a total value of $100,733.61.
• On Thursday, August 20th, Daljit Singh Aurora sold 67,741 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.51, for a total value of $102,288.91.
• On Friday, August 21st, Daljit Singh Aurora sold 20,553 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.59, for a total transaction of $32,679.27.
• On Wednesday, August 19th, Daljit Singh Aurora sold 30,918 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.65, for a total transaction of $51,014.70.
• On Wednesday, August 19th, Daljit Singh Aurora sold 31,000 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.65, for a total value of $51,150.00.
• On Monday, August 17th, Daljit Singh Aurora sold 55,016 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.50, for a total value of $82,524.00.
• On Monday, August 17th, Daljit Singh Aurora sold 91,690 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.50, for a total transaction of $137,535.00.
• On Tuesday, August 18th, Daljit Singh Aurora sold 34,987 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.59, for a total transaction of $55,629.33.
• On Tuesday, August 18th, Daljit Singh Aurora sold 34,162 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.58, for a total value of $53,975.96.

Neumora Therapeutics Price Performance

Shares of NMRA stock traded up $0.12 on Friday, reaching $1.63. The company had a trading volume of 498,604 shares, compared to its average volume of 765,644. The stock has a market capitalization of $306.28 million, a PE ratio of -1.33 and a beta of 2.75. The company has a quick ratio of 5.09, a current ratio of 4.50 and a debt-to-equity ratio of 1.19. The business's 50-day moving average is $1.60 and its 200 day moving average is $2.10. Neumora Therapeutics, Inc. has a one year low of $0.83 and a one year high of $3.65.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.01. Equities research analysts forecast that Neumora Therapeutics, Inc. will post -0.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Neumora Therapeutics

A number of hedge funds have recently bought and sold shares of NMRA. HBK Sorce Advisory LLC purchased a new position in Neumora Therapeutics during the second quarter worth about $26,000. Hsbc Holdings PLC purchased a new position in shares of Neumora Therapeutics in the 4th quarter worth approximately $27,000. Virtu Financial LLC bought a new position in shares of Neumora Therapeutics in the third quarter valued at approximately $31,000. Fred Alger Management LLC bought a new position in Neumora Therapeutics in the 4th quarter valued at $40,000. Finally, Canada Pension Plan Investment Board bought a new position in Neumora Therapeutics during the second quarter valued at about $41,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Royal Bank Of Canada dropped their price target on shares of Neumora Therapeutics from $7.00 to $5.00 and set an "outperform" rating for the company in a research note on Monday, July 13th. HC Wainwright reaffirmed a "buy" rating on shares of Neumora Therapeutics in a research note on Tuesday, July 28th. Needham & Company LLC lowered their target price on Neumora Therapeutics from $8.00 to $5.00 and set a "buy" rating for the company in a report on Tuesday, June 16th. Weiss Ratings lowered Neumora Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, August 14th. Finally, Mizuho dropped their target price on shares of Neumora Therapeutics from $6.00 to $4.00 and set an "outperform" rating on the stock in a research report on Thursday, June 18th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $6.57.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora's product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source